What the Yale Secret Shopper Study Means for Your Next Prescription
45 of 49 platforms prescribed with minimal oversight. Here's the patient-facing interpretation — and the four questions to ask before submitting your intake to any telehealth platform.
The July 2026 Yale/JAMA secret shopper study found that 45 of 49 GLP-1 telehealth platforms prescribed with minimal oversight — two-thirds with no documented clinician interaction. That's the headline. Here's what it actually means for you when you're trying to get a prescription.
The patient-facing interpretation
The study doesn't mean telehealth GLP-1 prescribing is inherently unsafe. It means the distribution of platform quality is wide. Platforms that prescribe without any clinician review exist alongside platforms that require documented provider evaluation, appropriate labs, and structured follow-up. The study makes the task of distinguishing them more urgent.
A licensed provider reviewed your specific medical history, current medications, contraindications, and approved your prescription based on that review — and there's a record of that review. This is different from an algorithm processing your intake and routing a prescription to a provider for rubber-stamp approval in under 60 seconds.
Four questions to ask before submitting your intake
- "Does a licensed provider review my intake before my prescription is approved?" A yes with specifics (video visit, async review with documentation) is good. A vague yes or no response is a flag.
- "Will I know who prescribed my medication?" Legitimate platforms provide prescriber name and license number. If the answer is unclear, that's a problem.
- "What labs are required before starting?" For GLP-1 at obesity doses, appropriate baseline labs are standard of care.
- "What does follow-up look like?" A protocol with scheduled check-ins and dose adjustment based on response is the responsible model.
What changed after the study
Regulatory attention intensified. State medical boards in California, New York, and Texas opened reviews of telehealth prescribing standards. The Federation of State Medical Boards issued guidance reiterating that prescribing without adequate patient evaluation may violate state practice standards. None of this immediately changes which platforms are prescribing responsibly — but it raises the cost of operating irresponsibly for the platforms that aren't.
Verified telehealth providers
Real provider visits, documented review. The opposite of what the study flagged.
Paid link Get started →Physician-reviewed prescriptions. Clinical documentation on file.
Paid link Get started →Licensed provider consult with verification before prescription approval.
Paid link Get started →